Get the app
US › Healthcare

Protara Therapeutics Inc (TARA)

US · Healthcare · Biotechnology

$2.32-3.33%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-21.7M
EPS
$-0.36
EPS estimate
$-0.33

EPS came in at -0.36 against a street estimate of -0.33 — a miss of 9.1%.

Key statistics

Market cap
$163.7M
Forward P/E
0.0
P/B
1.30
Book value
$2.73
EPS (TTM)
$-1.36
52-week high
$7.82
52-week low
$2.51
50-day MA
$3.62
200-day MA
$4.77
Beta
1.47

Analyst view

Analysts rate Protara Therapeutics Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $25.71.

Shareholding

Insiders
2.30%
Institutions
78.39%

Largest institutional holders

FundStake
HHG PLC8.81%
Jupiter Topco LLC7.95%
BlackRock Inc6.20%
Millennium Management LLC5.25%
Velan Capital Investment Management LP4.81%
Vanguard Capital Management, LLC3.89%
Blackstone Inc3.83%
Orbimed Advisors LLC3.76%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Protara Therapeutics Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.